ArticleDiagnostics (Basel, Switzerland)2023
Multimodal Spatiotemporal Deep Learning Framework to Predict Response of Breast Cancer to Neoadjuvant Systemic Therapy.
Article in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.
- Multimodal deep learning for predicting neoadjuvant treatment outcomes in breast cancer: a systematic review.Biology direct · 2025Pooled it
- Deep learning in multi-modal breast cancer data fusion: a literature review.Quantitative imaging in medicine and surgery · 2025Review
- [Artificial intelligence in predicting pathological complete response to neoadjuvant chemotherapy for breast cancer: current advances and challenges].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2025Review
- The Evolution and Clinical Impact of Deep Learning Technologies in Breast MRI.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2025Review
- Deep learning model for the early prediction of pathologic response following neoadjuvant chemotherapy in breast cancer patients using dynamic contrast-enhanced MRI.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current approaches to breast cancer therapy include neoadjuvant systemic therapy (NST). The efficacy of NST is measured by pathologic complete response (pCR). A patient who attains pCR has significantly enhanced disease-free survival progress. The accurate prediction of pCR in response to a given treatment regimen could increase the likelihood of achieving pCR and prevent toxicities caused by treatments that are not effective. Th early prediction of response to NST can increase the likelihood of survival and help with decisions regarding breast-conserving surgery. An automated NST prediction framework that is able to precisely predict which patient undergoing NST will achieve a pathological complete response (pCR) at an early stage of treatment is needed. Here, we propose an end-to-end efficient multimodal spatiotemporal deep learning framework (deep-NST) framework to predict the outcome of NST prior or at an early stage of treatment. The deep-NST model incorporates imaging data captured at different timestamps of NST regimens, a tumor's molecular data, and a patient's demographic data. The efficacy of the proposed work is validated on the publicly available ISPY-1 dataset, in terms of accuracy, area under the curve (AUC), and computational complexity. In addition, seven ablation experiments were carried out to evaluate the impact of each design module in the proposed work. The experimental results show that the proposed framework performs significantly better than other recent methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.